Promisng Alzheimer's Disease Drug Dimebon Fails
A promising Alzheimer's disease drug Dimebon worked no better than a placebo in a late-stage study. An unexpected disappointment after Dimebon, the potential blockbuster, stopped Alzheimer’s symptoms from worsening for a year in a prior test. Dimebon, failed to meet its primary and secondary goals improving thinking ability and overall daily function over six months in patients with mild to moderate Alzheimer's disease.
Losing a parent to suicide makes children more likely to die by suicide themselves and increases their risk of developing a range of major psychiatric disorders, according to a study led by Johns Hopkins Children’s Center. The study is believed to be the largest one to date regarding suicide risk of children whose parents committed suicide.
A report on the findings will appear in the May 2010 issue of the Journal of the American Academy of Child & Adolescent Psychiatry.
Adults who used the herbal supplement ginkgo biloba for several years did not have a slower rate of cognitive decline compared to adults who received placebo rather than Ginkgo biloba, according to a recent study published in the Journal of the American Medical Association (JAMA).